Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 7;17(1):185–193. doi: 10.4103/1673-5374.314312

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Neural Regeneration Research

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

PMC Copyright notice

ALDH2 agonist Alda-1 treatment of SCI increases the expression of BDNF, NT3, and MBP in the chronic phase (30 days) of a mouse model of SCI.

Western blot studies showing the increased expression levels of BDNF (A) and densitometry (B), NT3 (C), and densitometry (D), and IHC studies showing the increased expression levels of MBP (E; green) and cell counting (F) indicate that Alda-1 stimulates neurorepair process. Data are presented as the mean ± SD (n = 7). ***P < 0.001, vs. Sham; ++P < 0.01, +++P < 0.001, vs. SCI (one-way analysis of variance with Tukey’s post hoc test). Alda-1: N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide; ALDH2: aldehyde dehydrogenase 2; BDNF: brain-derived neurotrophic factor; MBP: myelin basic protein; NT3: neurotrophin-3; SCI: spinal cord injury.